Post Profile






FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease.
read more

share

Related Posts


FDA Licenses Sanofi Pasteur's New Influenza Vaccine Delivered By Intradermal Microinjection

Health : Medical News Today

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of Fluzo...

Dronedarone (Multaq) Reduced The Incidence And Duration Of Hospitalization In Patients With Atrial Fibrillation

Health : Medical News Today

New data from the landmark ATHENA trial showed that dronedarone significantly reduced the incidence and total duration of hospital stays among patients with atrial fibrillation / atrial flutter (AF/AFL). This post-hoc analysis was p...

Auvi-Q™, First Voice-Guided Epinephrine Auto-Injector For Patients With Life-Threatening Allergies, Receives FDA Approval

Health : Medical News Today

Breakthrough device design talks patients and caregivers through the injection process Sanofi (EURONEXT: SAN and NYSE: SNY) have announced that the U.S. Food and Drug Administration (FDA) has approved Auvi-Q (epinephrine injection, ...

New England Journal Of Medicine Publishes Results From The Landmark ATHENA Trial With Multaq(R) (dronedarone) In Atrial Fibrillation

Health : Medical News Today

Sanofi Aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq(R) (dronedarone), in addition to standard thera...

FDA Approves Multaq To Treat Heart Rhythm Disorder

Health : Medical News Today

The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved...

Comments


Copyright © 2016 Regator, LLC